All Provinces and Territories Sign Rare Disease Drug Agreements
Ottawa, April 1, 2025 – Quebec signed a bilateral agreement under the federal government’s National Strategy for Drugs for Rare […]
Drugs for Rare Diseases (DRD)
Increasing timely access to medicines for patients suffering from rare diseases.
One in 12 Canadians, two-thirds of them children, lives with a rare disease. IMC advocates for policies that improve and accelerate access to the medicines and treatments these patients urgently need.
Canada needs to deliver on its rare disease strategy to enable better patient care and timely access to treatments.
News
Innovative Medicines Canada welcomes bilateral agreements between the Government of Canada and Province of British Columbia to improve patient access to drugs for rare diseases
Ottawa, July 24, 2024 – Innovative Medicines Canada (IMC) is encouraged by the announcement that the federal government and the […]
A year later, none of the $1.5B for rare disease has flowed to patients
Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.
Government Submissions
Addendum to IMC Submission on Drugs for Rare Diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
Towards a Value-based and Pan-Canadian Rare Disease Strategy
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
Infographics & Data
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
Analysis & Reports
Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
Newsroom
Breaking down key developments in the life sciences sector for members, policy influencers, and Canadians.
About
Learn how our member companies, which range from early-stage startups to established organizations, are advancing healthcare through the discovery and development of new medicines and vaccines.
